Perinatal stress-induced hyperinsulinism is a common cause of persistent hypoglycemia in at-risk neonates. The hypoxia-inducible factor-1 (HIF-1) pathway regulates cellular adaptation in hypoxic conditions through hypoxia response elements. We hypothesize that perinatal hypoxia leads to activation of the HIF1 pathway causing increased insulin secretion from neonatal β-cells. We examined glucose homeostasis and insulin secretion in NeuroD1-Cre;VhlLoxp/Loxp(VhlbetaKO) and in hypoxic wild type (WT) mouse pups in the first week of life. In VhlbetaKO pups postnatal day 8 (P8), plasma glucose was significantly lower compared to littermate controls (76 vs 129 mg/dL). Plasma insulin (0.54 vs 0.27 ng/mL) and the insulin to glucose ratio were significantly greater in VhlbetaKO pups indicating a failure to suppress insulin secretion. VhlbetaKO islet perifusion showed the lower plasma glucose level was due to a lower threshold (5 mM) for glucose stimulated insulin secretion (GSIS) compared to controls (10 mM). To assess the consequences of perinatal hypoxia, we exposed WT mouse pups to hypoxia (10% O2) between embryonic day 18 and P6. Islets from the hypoxia exposed pups had a lower GSIS threshold (3 mM) compared to islets from normoxic pups (5 mM) at P6. Hypoxic islets also had a lower insulin secretion threshold when stimulated with BCH, a glutamate dehydrogenase activator, or tolbutamide, a KATP channel inhibitor, suggesting that HIF1 pathway activation leads to a decreased stimulus threshold for secretion at or distal to the KATP channel. Patch clamps revealed that β-cells from hypoxic pups were more depolarized than normoxic controls. Our results show that the HIF1 pathway is critical for setting the GSIS threshold and a potential mediator of PSHI. We posit perinatal hypoxia and the HIF1 pathway at the core of β-cell maturational defects leading to increased risk of diabetes in adult life and the long-sought answer to the cause of perinatal stress-induced hyperinsulinism.

Disclosure

C.Juliana: Research Support; Crinetics Pharmaceuticals, Inc., Twist Bioscience, AmideBio. D.De leon: Consultant; Zealand Pharma A/S, Crinetics Pharmaceuticals, Inc., Eiger BioPharmaceuticals, Hanmi Pharm. Co., Ltd., Research Support; Ultragenix, Crinetics Pharmaceuticals, Inc., Hanmi Pharm. Co., Ltd., Rezolute, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.